Price
No data yet.
Social Signal Score
Revenue
$8.1K-86.26%Company Profile
- CEO
- Robert Huizinga
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 20
- Beta
- 0.31
- Country
- CA
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -28.64
Financials
Revenue
$8.1K-86.3%Net Income
$-834.0KEBITDA
$-775.8KFree Cash Flow
$-634.6KEPS (diluted)
$-0.00Shares Outstanding (diluted)
205.06M+484.9%Operating Expenses
$777.2KCash & Debt
$855.1KReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $427.5K | $-2.72M | $-0.02 |
| 2024 | $2.08M | $6.10M | $-0.02 |
| 2023 | $149.0K | $-5.03M | $-0.04 |
| 2022 | $2.67M | $-3.89M | $-0.03 |
| 2021 | $1.61M | $-4.60M | $-0.04 |
| 2020 | $1.34M | $-3.72M | $-0.03 |
| 2019 | $1.69M | $-960.2K | $-0.01 |
| 2018 | $506.3K | $-3.26M | $-0.04 |
| 2017 | $1.04M | $-2.79M | $-0.05 |
| 2016 | $244.8K | $-2.55M | $-0.07 |
| 2015 | $104.6K | $-1.71M | $-0.08 |
| 2014 | $41.9K | $-1.61M | $-0.08 |
| 2013 | $159.9K | $-1.45M | $-0.08 |
| 2012 | $0.00 | $-1.46M | $-0.10 |
Valuation
KNBIFhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (2)
- Newsglobenewswire.com·6h ago·Neutral
Kane Biotech to Host Commercial Update Webcast on September 16 Board Chair Philip Renaud, leading wound-care surgeon Dr. John C. Lantis and Interim CEO Dr. Robert Huizinga to discuss Kane's commercial progress, clinical relevance and operational priorities Board Chair Philip Renaud, leading wound-care surgeon Dr. John C. Lantis and Interim CEO Dr. Robert Huizinga to discuss Kane's commercial progress, clinical relevance and operational priorities
View source ↗ - Newsglobenewswire.com·12d ago·Neutral
Kane Biotech Announces Second Quarter 2026 Financial Results WINNIPEG, Manitoba, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announces today its second quarter 2026 financial results.
View source ↗
Earnings
Thu, Nov 26(in 3 months)
Estimates and results for KNBIF via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.